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AbstrAct:
Recent clinical trials with selective inhibitors of the BRAF and MEK kinases have 
shown promising results in patients with tumors harboring BRAF V600 mutations. 
However, as has been observed previously with similarly successful targeted 
therapies, acquired resistance to these agents is an emerging problem that limits 
their clinical benefit. Several recent studies from our laboratory and others have 
investigated the causes of acquired resistance to BRAF and MEK inhibitors, and 
multiple  resistance  mechanisms  have  been  identified.  Here,  we  review  these 
mechanisms and suggest that they can be broadly grouped into two main classes: 
ERK-dependent and ERK-independent. We also propose distinct therapeutic 
strategies that might be employed to overcome each class of acquired resistance.
the rAF-MeK-erK pAthwAy And 
cAncer
The RAF-MEK-ERK pathway regulates many 
important cellular processes (reviewed in [1-3]). 
Classically, signaling through this pathway is driven 
by growth factor receptor activation of RAS family 
GTPases, including HRAS, KRAS, and NRAS. Activated 
RAS proteins can complex with and activate members 
of the RAF kinase family—ARAF, BRAF, and CRAF. 
Once activated, RAF kinases phosphorylate and activate 
the MEK (mitogen-activated or extracellular signal-
related protein kinase kinase) kinases, MEK1 and MEK2, 
which subsequently phosphorylate and activate ERK1 
and ERK2. ERK (extracellular signal-regulated kinase) 
kinases phosphorylate a number of substrates with critical 
roles in regulating gene expression, proliferation, and cell 
survival.
Consistent with its role as a key regulatory pathway 
for cell survival and proliferation, RAF-MEK-ERK 
signaling is frequently dysregulated in cancer. RAF-
MEK-ERK signaling can be driven by aberrant activation 
of growth factor receptor tyrosine kinases (RTKs) or by 
oncogenic mutations of intracellular components of this 
pathway. Indeed, activating RAS mutations (occurring 
most often in KRAS, followed by NRAS) are the most 
common oncogenic mutations observed thus far in human 
cancer [4]. Similarly, activating BRAF mutations are 
found in ~7% of human cancers, with particularly high 
frequency in melanoma (50-70%), papillary thyroid 
cancers (40%), and colorectal cancers (10-15%) [5]. Over 
95% of BRAF mutations are point mutations involving 
valine 600 (V600) with more than 90% of these mutations 
encoding a substitution of V600 with a glutamic acid 
(V600E). BRAF V600 mutations lead to constitutive 
BRAF kinase activity and can promote oncogenesis 
in mouse tumor models [6-9]. As a result, considerable 
effort has been devoted to the development of therapeutic 
strategies directed against mutant BRAF and its key 
effectors.
brAF And MeK inhibitors in the 
treAtMent oF brAF MutAnt 
cAncers
Preclinical data has demonstrated that most BRAF 
mutant human tumor-derived cell lines are exquisitely 
sensitive to pharmacologic inhibition of RAF-MEK-
ERK signaling. Thus, selective BRAF and MEK kinase 
inhibitors potently block cell proliferation and induce Oncotarget 2011; 2:  336 - 346 337 www.impactjournals.com/oncotarget
apoptosis in BRAF mutant cancer models and show high 
selectivity for cancers with BRAF mutations [10-12]. As 
a result, several BRAF and MEK inhibitors are currently 
in clinical development. Consistent with preclinical 
observations, while early clinical trials with RAF and 
MEK inhibitors in unselected patient populations 
produced few responses [13-15], recent clinical trials 
have focused on administering these agents specifically 
to patients with BRAF mutant tumors and have produced 
encouraging results. In a Phase I/II trial of the selective 
BRAF inhibitor PLX4032 in melanoma patients harboring 
the BRAF V600 mutation, 81% of patients achieved an 
objective response (defined as a reduction in tumor size 
of at least 30%) [16]. Interestingly, in a small study of 
25 BRAF V600 mutant colorectal cancer patients treated 
with PLX4032, only 1 patient (5%) achieved a partial 
response, with an additional 4 patients (20%) achieving 
stable disease, suggesting that different tumor types may 
exhibit varied dependence on mutant BRAF [17]. Another 
selective BRAF inhibitor GSK2118436 produced a 
60% response rate in patients with BRAF V600 mutant 
melanomas [18]. In early studies, the MEK inhibitor 
GSK1120212 produced a 21% response rate in BRAF 
V600 mutant melanoma patients [19]. While this response 
rate was lower than that observed for the two selective 
BRAF inhibitors mentioned above, an additional 54% 
of patients achieved stable disease with GSK1120212, 
suggesting that MEK inhibitors may still play an important 
clinical role in the treatment of BRAF mutant cancers.
One potential reason that BRAF inhibitors have 
shown higher response rates than MEK inhibitors in BRAF 
V600 mutant melanomas relates to a unique characteristic 
of RAF signaling that was elucidated during the past 
year by several elegant studies [20-22]. These groups 
found that while BRAF inhibitors potently inhibited ERK 
phosphorylation in BRAF V600 mutant cells, BRAF 
inhibitors failed to inhibit, and in some cases paradoxically 
increased, levels of phosphorylated ERK (P-ERK) in cells 
with wild-type BRAF. Activation of P-ERK by BRAF 
inhibitors in BRAF wild-type cells was more pronounced 
in cells with active RAS, either due to RAS mutation or 
to activation of RAS by upstream signaling components, 
such as RTKs. While mutant BRAF signals as a monomer, 
these groups found that in the presence of active RAS, 
wild-type BRAF forms homodimers or heterodimers 
with other RAF proteins, such as CRAF. When a BRAF 
inhibitor binds to one member of a RAF dimer, it blocks 
the catalytic activity of the protein to which it is bound, 
but it also induces transactivation of the inhibitor-free 
member of the RAF dimer, leading to an increase in 
catalytic activity and enhanced phosphorylation of the 
RAF substrate MEK. As a result, P-ERK inhibition by 
BRAF inhibitors is restricted to BRAF mutant cells, 
enabling a high dose of BRAF inhibitor to be administered 
without causing the toxic effects of ERK inhibition in 
normal tissues. Conversely, MEK inhibitors inhibit ERK 
phosphorylation in all cells, potentially leading to toxicity 
caused by suppression of P-ERK in normal tissues, and 
consequently limiting the dose that can be administered in 
patients. In other words, the narrower therapeutic window 
of MEK inhibitors may explain why BRAF inhibitors 
have produced higher response rates than MEK inhibitors 
in patients with BRAF mutant tumors.
While the initial response rates seen in BRAF 
mutant melanomas with BRAF and MEK inhibitors are 
encouraging, previous experience with similarly effective 
targeted therapies predicts that acquired drug resistance 
will  be  a  major  factor  limiting  the  clinical  benefit  of 
these agents. Indeed, despite dramatic initial responses, 
the median time to progression of patients treated 
with PLX4032 was 7 months [16]. Understanding the 
mechanisms by which patients’ tumors acquire resistance 
to targeted therapies can potentially lead to strategies to 
overcome resistance. Accordingly, significant effort has 
been devoted recently to studying acquired resistance to 
BRAF and MEK inhibitors in BRAF mutant cancers.
Acquired resistAnce to brAF And 
MeK inhibitors
Preclinical modeling of acquired drug resistance 
has been a useful tool for predicting the resistance 
mechanisms that emerge in patients receiving targeted 
cancer therapies. Previously, this approach has predicted 
the resistance mechanisms that occur clinically in many 
instances, including erlotinib-resistance in EGFR mutant 
lung cancer, imatinib-resistance in BCR-ABL translocated 
leukemia, resistance to Smoothened inhibitors in 
Patched1-deficient  medulloblastoma,  and  resistance  to 
ALK inhibitors in ALK-translocated lung cancers [23-
28]. In several cases, these findings have led to strategies 
to overcome resistance, which are now being used in the 
clinic. 
To date, preclinical modeling has identified multiple 
potential mechanisms of acquired resistance to BRAF or 
MEK inhibitors (Fig. 1), and some of these mechanisms 
have been validated clinically. In general, these resistance 
mechanisms, reviewed below, fall into two broad 
categories—those that retain their dependence on ERK 
signaling and those that do not. We will refer to these 
two classes as ERK-dependent and ERK-independent 
mechanisms of acquired resistance.
erK-dependent MechAnisMs oF 
Acquired resistAnce
The vast majority of acquired resistance mechanisms 
to BRAF or MEK inhibitors that have been identified to date 
lead to reactivation of ERK signaling despite the presence 
of inhibitor. This finding underscores the importance of 
ERK signaling for the continued proliferation and survival Oncotarget 2011; 2:  336 - 346 338 www.impactjournals.com/oncotarget
of BRAF mutant cancer cells. In general, mechanisms 
of acquired resistance to targeted therapies commonly 
employ  either  mutation  or  amplification  of  the  drug 
target itself or alterations which do not involve the drug 
target but that activate parallel or downstream signaling 
pathways to circumvent the activity of the drug [23-34]. In 
resistant BRAF mutant tumor models, examples of each of 
these common mechanisms has been identified in resistant 
BRAF mutant tumor models that lead to reactivation of 
ERK signaling.
point mutations in MeK1
Emery et al identified a MEK1 point mutation in a 
resistant focus of disease in a patient with V600E mutant 
melanoma who had originally responded to the MEK 
inhibitor AZD6244 [35]. Through a mutagenesis screen of 
MEK1, the authors also identified several additional point 
mutations that could potentially lead to MEK inhibitor 
resistance. The majority of these mutations clustered 
within or near the allosteric drug-binding pocket and were 
hypothesized  to  interfere  with  inhibitor  binding.  Other 
point mutations were identified outside of the drug-binding 
pocket  and  were  thought  to  influence  intrinsic  MEK 
kinase activity or to affect protein conformation. These 
point mutations severely attenuated the ability of MEK 
inhibitors to inhibit ERK phosphorylation. Some MEK1 
mutations, including the P124L mutation identified in a 
patient’s AZD6244-resistant melanoma, also led to cross-
resistance to BRAF inhibitors, presumably by causing 
activation of MEK downstream of BRAF. Interestingly, 
later work by this same group identified a different MEK1 
point mutation (C121S) in a post-relapse biopsy from a 
patient with clinically acquired resistance to the BRAF 
inhibitor PLX4032, demonstrating that MEK1 mutations 
can arise as a potential mechanism of acquired resistance 
to BRAF inhibitors as well [36]. Interestingly, although 
the MEK1 P124L point mutation conferred resistance 
to MEK or BRAF inhibitors alone, the combination of 
a MEK inhibitor and BRAF inhibitor could overcome 
resistance in this setting.
To date, no secondary BRAF mutations have been 
identified in BRAF inhibitor-resistant pre-clinical models 
or in biopsies from patients with clinically acquired 
BRAF inhibitor resistance. Nazarian et al screened twelve 
tumor biopsies from patients with clinically acquired 
resistance to PLX4032 and did not observe any secondary 
BRAF mutations [37]. “Ultra-deep” sequencing of these 
tumors also failed to reveal any evidence of secondary 
BRAF mutations. Notably, the BRAF T529 “gatekeeper” 
mutation has been shown to confer resistance to BRAF 
inhibition when introduced into BRAF mutant cell 
lines and in genetically engineered mouse models [38]. 
Therefore, while it is possible that secondary BRAF 
mutations may be identified as more tumors with acquired 
resistance to BRAF inhibitors are analyzed, it does not 
appear that secondary BRAF mutations are a common 
cause of acquired BRAF inhibitor resistance in the clinic. 
Amplification of mutant BRAF
While secondary mutations in BRAF have not been 
identified as a cause of BRAF or MEK inhibitor resistance, 
our laboratory recently identified selective amplification 
of the mutant BRAF allele as the mechanism underlying 
acquired resistance in two independent BRAF mutant 
colorectal cancer cell lines selected for resistance to 
the MEK inhibitor AZD6244 [39]. BRAF amplification 
was also recently identified by another laboratory as the 
mechanism of acquired resistance to MEK inhibitors 
in a different BRAF mutant colorectal cell line model, 
corroborating  these  findings  [40].  Resistant  BRAF-
amplified  clones  were  also  cross-resistant  to  BRAF 
inhibitors, although to a slightly lesser degree. Surprisingly, 
even though MEK inhibitors act downstream of BRAF, 
BRAF gene amplification dramatically reduced the ability 
of AZD6244 to inhibit ERK phosphorylation and, as a 
consequence, to inhibit cell proliferation and survival. 
Although  BRAF  amplification  arose  as  an  acquired 
resistance mechanism in vitro, BRAF amplification has 
not been identified as a mechanism of acquired resistance 
in clinical samples, given that few MEK inhibitor-resistant 
tumor  biopsies  are  available.  However,  we  identified 
pre-existing  BRAF  amplification  in  a  treatment-naive 
Figure 1: Mechanisms of acquired resistance to BRAF 
and  MEK  inhibitors  in  BRAF  mutant  cancers.  A 
schematic of the RAF-MEK-ERK signaling pathway is shown 
with BRAF in red. Alterations of signaling pathway components 
leading to resistance to BRAF or MEK inhibitors are indicated 
by number. Resistance mechanisms classified as ERK-dependent 
are shown in the left panel, and mechanisms classified as ERK-
independent are shown in the right panel.
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BRAF mutant colorectal cancer, suggesting that BRAF 
amplification could also be a cause of de novo resistance 
to BRAF and MEK inhibitors in the clinic.
We found that the mechanism by which BRAF 
amplification led to BRAF and MEK inhibitor resistance 
hinged upon hyperactivation of MEK. We observed that 
the levels of phosphorylated MEK (P-MEK) in resistant 
cells were 5 to 6 times higher than the basal levels seen 
in parental cells. Careful evaluation of the dose-response 
relationship between BRAF inhibitor treatment and 
phosophorylation of MEK and ERK revealed that, in 
resistant cells, levels of P-MEK could be reduced by 
~50% before any noticeable decrease in P-ERK levels 
was observed. This was in stark contrast to parental cells, 
in which a ~50% decrease in P-MEK levels led to a ~50% 
decrease in P-ERK levels. These findings suggested that 
the high levels of P-MEK in resistant cells (driven by 
BRAF amplification) were in excess of levels required 
for near-maximal ERK phosphorylation. As a result, a 
much higher concentration of BRAF or MEK inhibitor 
was required to fully suppress ERK phosphorylation in 
resistant cells, either by reducing excess P-MEK levels 
(as in the case of the BRAF inhibitor) or by inhibiting 
excess MEK activity (as in the case of the MEK inhibitor). 
However, if resistant cells were treated with a low dose 
of BRAF inhibitor sufficient to reduce levels of P-MEK 
to amounts observed under basal conditions in parental 
cells, the ability of MEK inhibitors to suppress P-ERK 
was completely restored. Accordingly, while resistant 
cells were insensitive to BRAF or MEK inhibitors 
individually, combined BRAF and MEK inhibition fully 
overcame resistance and induced dramatic apoptosis and 
growth inhibition in these cells. Furthermore, combined 
BRAF and MEK inhibition was also more effective in 
parental cells, suggesting a possible broader utility for 
combinatorial targeting of the RAF-MEK pathway in 
BRAF mutant cancers.
This mechanism underlying the resistance to BRAF 
and MEK inhibitors caused by BRAF amplification has 
potential implications for other models of resistance in 
BRAF mutant tumors. Since excess levels of activated 
and phosphoryated MEK underlie the mechanism of 
resistance to BRAF and MEK inhibitors, it is possible 
that other changes that lead to similar degrees of MEK 
hyperactivation could cause a similar mode of resistance. 
For example, excessive upstream input from receptor 
tyrosine kinases (RTKs), RAS or RAF proteins, or other 
activators of MEK, could also potentially lead to MEK 
hyperactivation and result in similar resistance to BRAF 
or MEK inhibitors. 
Elevated CRAF activity
Montagut et al identified elevated CRAF activity as 
a mechanism of resistance to the BRAF inhibitor AZ628 
in pre-clinical studies [41]. In AZ628-resistant clones 
generated in vitro from a BRAF V600 mutant melanoma 
cell line, P-ERK levels were maintained despite treatment 
with the inhibitor. Elevated CRAF protein levels were 
present in resistant clones, relative to drug-sensitive 
parental cells, whereas levels of ARAF and BRAF 
were unchanged. No CRAF gene amplification and no 
increase in CRAF transcript were noted, suggesting that 
elevated CRAF levels arose from a post-transcriptional 
mechanism. In this model, tumor cells appear to have 
switched their dependency from BRAF to CRAF. Thus, 
resistant clones were sensitive to CRAF knockdown 
or to Hsp90 inhibitors, which down-regulated CRAF 
protein levels. CRAF overexpression in parental cells also 
produced AZ628 resistance. Interestingly, resistant clones 
with elevated CRAF levels retained some sensitivity to 
MEK inhibitors, although with reduced potency.
Activating NRAS mutation
Nazarian et al recently identified NRAS mutations as 
a mechanism of acquired resistance to the BRAF inhibitor 
PLX4032 [37]. NRAS mutations are present in 15-30% of 
melanomas, but are rarely coincident with BRAF mutations 
[42, 43]. Cell lines resistant to PLX4032 were derived 
from three melanoma cell lines with BRAF mutations. 
In one of these cell lines, an NRAS Q61K mutation was 
identified. An NRAS Q61K mutation was also identified 
in an isolated nodal metastasis from a patient with BRAF 
mutant melanoma, which progressed after an initial 
response to PLX4032. Interestingly, a distinct NRAS 
mutation (Q61R) was identified in a second progression 
site in the same patient. In resistant cells in vitro, both 
P-MEK and P-ERK levels were maintained despite the 
presence of BRAF inhibitor. It is therefore likely that 
mutant NRAS leads to activation of MEK by signaling 
through RAF isoforms other than BRAF. However, both 
the PLX4032-resistant cell line and a short-term culture 
line from the above patient’s resistant disease focus—
each harboring an acquired NRAS mutation—retained 
sensitivity to MEK inhibitor alone and to the combination 
of PLX4032 and a MEK inhibitor. Interestingly, in early 
clinical trials with MEK inhibitors in unselected patient 
populations, responses to single agent MEK inhibitor 
were observed in patients with NRAS mutant melanomas, 
including one complete response [15]. These data suggest 
that MEK inhibitors or a RAF/MEK inhibitor combination 
could be a potential therapy to overcome NRAS-mediated 
resistance to BRAF inhibitors.
Increased levels of COT/Tpl2
Johannessen et al used an ORF expression library 
encoding approximately three-quarters of the human 
“kinome” to identify kinases that confer resistance to the 
BRAF inhibitor PLX4720 when they are overexpressed Oncotarget 2011; 2:  336 - 346 340 www.impactjournals.com/oncotarget
in sensitive BRAF V600E melanoma cell lines [44]. Nine 
kinases were identified, two of which caused P-MEK and 
P-ERK levels to be maintained despite the presence of 
PLX4720. These two kinases were CRAF (consistent with 
the findings of Montagut et al, above [41]) and COT/Tpl2, 
encoded by MAP3K8. These data suggest that activation 
of MEK-ERK signaling by COT represents a novel RAF-
independent mechanism of MEK activation. Interestingly, 
COT levels were observed to increase in cell lines 
treated with BRAF inhibitors, suggesting that COT may 
be involved with feedback regulation of MEK activity. 
Consistent with these findings, in the biopsies of two of 
three patients taken during treatment with PLX4032, COT 
transcript levels were elevated relative to pre-treatment 
biopsies. In one patient who was biopsied post-relapse, 
levels of COT transcript were elevated relative to pre-
treatment and on-treatment biopsies, suggesting that COT 
may contribute to acquired resistance to BRAF inhibitors 
in the clinic. The authors also identified two cell lines with 
copy number gains at the MAP3K8 locus that expressed 
high levels of COT. These cell lines were resistant to 
PLX4720. Interestingly, even though COT appears to 
activate ERK through MEK, these cell lines and cell lines 
overxpressing exogenous COT were also resistant to MEK 
inhibitors. One possible explanation for this observation is 
that high COT levels might contribute to MEK inhibitor 
resistance by causing MEK hyperactivation, similar to 
the mechanism observed for BRAF amplification [39]. 
Accordingly, combined BRAF and MEK inhibition was 
able to overcome resistance caused by elevated COT 
levels.
ERK-independent  mechanisms  of  acquired 
resistance
As discussed above, the majority of the resistance 
mechanisms to BRAF and MEK inhibition that have been 
identified lead to ERK reactivation and retain dependence 
on ERK signaling. While this underscores the importance 
of the RAF-MEK-ERK pathway in melanoma proliferation 
and survival, in the last few months several examples of 
resistance mechanisms have been reported that do not rely 
on sustained ERK signaling, indicating that other “ERK-
independent” pathways can compensate for loss of ERK 
activity and can maintain the tumorigenicity of BRAF 
V600E melanoma in the absence of ERK activation.
PDGFRβ overexpression
In  the  recent  study  by  Nazarian  et  al,  discussed 
above, of the three BRAF mutant melanoma cell lines 
made resistant to PLX4032, one resistant cell line was 
found to have acquired an NRAS mutation and maintained 
P-ERK levels despite the presence of BRAF inhibitor 
[37]. In the other two models, PLX4032 inhibited ERK 
phosphorylation to a similar degree as it did in the parental 
cell lines. The ability of these resistant cell line models 
to proliferate and survive despite suppression of P-ERK 
by PLX4032 suggested activation of “ERK-independent” 
proliferation and survival signals. Consistent with the 
lack of dependence on the ERK pathway demonstrated 
by these resistant cell line models, treatment with a 
MEK inhibitor or combined MEK and BRAF inhibition 
failed to overcome resistance, as it did with the ERK-
dependent models discussed above. Comparison of 
the microarray gene expression profiles of parental and 
resistant cells revealed overexpression of several RTKs 
in the resistant cells, including KIT, MET, EGFR and 
PDGFRβ. Of these four RTKs, only EGFR and PDGFRβ 
showed increased protein expression in the resistant cell 
lines, and only PDGFRβ displayed increased activation-
associated tyrosine phosphorylation in resistant cells. 
Importantly, the authors found that four of eleven clinical 
post-relapse biopsies from melanoma patients treated 
with PLX4032 showed increased PDGFRβ expression, 
relative to pre-treatment biopsies. To validate PDGFRβ 
as the cause of resistance in their cell line models, the 
authors demonstrated that RNAi-mediated knockdown of 
PDGFRβ in resistant cells led to growth inhibition in the 
presence of PLX4032. However, PDGFRβ knockdown 
did not restore an apoptotic response in these cells in 
the presence of PLX4032, suggesting that PDGFRβ 
overexpression may not be the only mechanism of 
resistance in these cells. Consistent with this possibility, 
the combination of the PDGFRβ inhibitor imatinib and 
PLX4032 did not restore sensitivity to resistant cell lines. 
Therefore, it is conceivable that an additional mechanism 
could be contributing to resistance, possibly involving 
one of the other RTKs whose expression was increased in 
resistant cells. Still, this model of resistance demonstrates 
that BRAF or MEK inhibitor resistance can arise in the 
absence of ERK reactivation and that RTKs may promote 
resistance through activation of ERK-independent 
proliferation and survival pathways.
IGF1R activation
Villanueva  et  al  recently  identified  another  RTK-
driven resistance mechanism through in vitro modeling 
of BRAF inhibitor resistance in BRAF V600E melanoma 
cell lines [45]. In cell lines made resistant to the BRAF 
inhibitor SB-590885, P-ERK was no longer suppressed 
by BRAF inhibition, suggesting activation of MEK-ERK 
signaling through another RAF isoform. Interestingly, 
knockdown of individual RAF isoforms revealed that no 
dominant RAF isoform controlled MEK-ERK signaling 
in resistant cells, unlike the situation observed with 
CRAF by Montagut et al [41]. Rather, P-ERK could only 
be suppressed if all three RAF isoforms were inhibited 
simultaneously. Alternatively, MEK inhibition was also 
capable of blocking ERK phosphorylation. These findings Oncotarget 2011; 2:  336 - 346 341 www.impactjournals.com/oncotarget
suggest that ERK is still activated in a MEK-dependent 
manner in the resistant cells, but that activation of MEK 
can proceed through any of the three RAF isoforms, 
consistent with activation of an upstream activator of 
RAF signaling. However, despite complete inhibition of 
P-ERK, MEK inhibition produced only cytostatic effects 
on resistant cells and failed to induce apoptosis, as it did in 
parental cells, suggesting activation of an ERK-dependent 
survival pathway in the resistant cells.
Because RTKs can signal through multiple RAF 
isoforms by activation of RAS proteins, and since RTKs 
activate multiple signaling pathways in addition to RAF-
MEK-ERK, the authors investigated whether resistant 
cells showed differences in RTK phosphorylation relative 
to parental cells. More than one RTK exhibiting differential 
phosphorylation  was  identified  by  phospho-RTK  array 
analysis, including IGF1R. However, pharmacologic 
inhibition of IGF1R decreased proliferation of resistant 
cells, and combined inhibition of IGF1R and MEK induced 
dramatic apoptosis, suggesting that ERK-independent 
survival signaling was mediated by IGF1R in resistant 
cells. While surface expression of IGF1R was found 
to be increased in resistant cells, the exact mechanism 
leading to increased IGF1R activation was not identified. 
In addition to activating the RAF-MEK-ERK pathway, 
IGF1R and other RTKs are known to activate PI3K-AKT 
signaling, which is known to be an important regulator 
of cell survival and proliferation [46, 47]. Resistant 
cells displayed elevated levels of phosphorylated AKT 
(P-AKT) compared to parental cells, and IGF1R inhibition 
could reduce P-AKT levels in resistant cells. Combined 
pharmacologic inhibition of PI3K and MEK was also able 
to induce apoptosis in resistant cells, indicating that the 
PI3K-AKT pathway mediated ERK-independent survival 
signals in these resistant cell line models.
Taken together, these two models of resistance 
driven by RTKs indicate that RTK-mediated resistance 
to BRAF or MEK inhibition highlights the complexity 
of signaling in resistant cells. Although in each resistance 
model, a dominant RTK was identified (e.g. PDGFRβ or 
IGF1R) that contributed to the majority of the signaling 
changes and to the decrease in drug sensitivity observed 
in resistant cells, there was evidence in each model that 
additional signaling pathways, perhaps involving other 
RTKs, were contributing to resistance. First, in each model, 
multiple RTKs were found to be elevated or to display 
increased phosphorylation, suggesting that other RTKs 
could contribute in some way to resistance. Second, in 
each model, inhibition of the dominant RTK, either using 
pharmacologic inhibitors or RNAi-mediated knockdown, 
was not sufficient to completely reverse all of the changes 
in signaling and sensitivity seen in the resistant cells. 
In the study by Nazarian et al, PDGFRβ knockdown 
blocked proliferation, but failed to induce apoptosis, even 
in the presence of BRAF inhibitor [37]. Furthermore, 
pharmacologic inhibition of PDGFRβ with imatinib did 
not restore sensitivity of resistant cells in the presence or 
absence of BRAF inhibitor. In the study by Villanueva et 
al, pharmacologic inhibition of IGF1R in combination 
with MEK was able to restore an apoptotic response in 
resistant cells [45]. However, inhibition of IGF1R could 
not restore the ability of BRAF inhibitor to suppress 
P-ERK, and, as a result, the addition of BRAF inhibitor 
did not lead to a greater reduction in cell viability 
compared  to  IGF1R  inhibition  alone.  These  findings 
suggest that the signaling through multiple RAF isoforms 
to MEK observed in resistant cells may not be due to 
increased IGF1R activation, but rather may involve other 
signals, perhaps from one of the other RTKs (e.g. MET) 
noted to demonstrate increased phosphorylation in their 
analysis of resistant cells. The complexity of each of these 
RTK-driven resistance models indicates that both the 
identification and subsequent targeting of the responsible 
RTK may be challenging in patients with BRAF mutant 
cancers who relapse while on treatment with BRAF or 
MEK inhibitors.
One potential strategy to overcome this problem 
would be to target common signaling nodes activated by 
RTKs in resistant cells, rather than attempting to target 
specific  RTKs.  In  addition  to  activating  RAF-MEK 
signaling, the PI3K-AKT pathway is a major signaling 
output of RTKs, and several studies have shown that 
inhibiting PI3K signaling in combination with RAF-MEK 
signaling is sufficient to induce apoptosis and suppress 
proliferation in RTK-driven cancer models [48-50]. 
Accordingly, as demonstrated by Villanueva et al, treatment 
of resistant cells with increased IGF1R activation with 
the combination of PI3K and MEK inhibitors restored an 
apoptotic response [45]. While this inhibitor combination 
was not tested in the PDGFRβ-driven resistance model 
discussed above, one might predict that combined PI3K 
and RAF-MEK inhibition would overcome resistance in 
this model as well. In support of this hypothesis, another 
in vitro model of BRAF inhibitor resistance in BRAF 
mutant melanoma was recently reported by Jiang et al 
[51]. While the exact mechanism of resistance was not 
identified, the mechanism appeared highly dependent on 
extracellular signals and serum concentration, and resistant 
cells showed increased levels of P-AKT, suggesting 
that activation of PI3K signaling, perhaps by RTKs, 
could also be involved in promoting resistance. In this 
model, treatment of resistant cells with the combination 
of a PI3K inhibitor and a BRAF inhibitor was able to 
overcome resistance. Collectively, these results suggest 
that co-targeting the PI3K and RAF-MEK pathways 
could constitute a potential strategy to overcome ERK-
independent mechanisms of BRAF or MEK inhibitor 
resistance, including RTK-driven resistance.Oncotarget 2011; 2:  336 - 346 342 www.impactjournals.com/oncotarget
iMplicAtions And therApeutic 
strAtegies
While the recent clinical successes of BRAF and 
MEK inhibitors in BRAF mutant cancers are encouraging, 
many of the responses to therapy have been short-lived 
due to rapid development of acquired resistance [16]. As 
a result, there is an urgent clinical need for therapeutic 
strategies for patients with BRAF mutant cancers who 
eventually progress on BRAF or MEK inhibitor therapy. 
The in vitro resistance models reviewed herein suggest that 
the most appropriate choice of therapy for patients with 
recurrent disease may depend on whether that particular 
patient’s resistant tumor is driven by an ERK-dependent 
or ERK-independent mechanism. As shown in Table 1, 
ERK-dependent resistant models retain sensitivity to 
combined treatment with BRAF and MEK inhibitors. 
It is important to note that, while the combination of 
BRAF and MEK inhibitors was not tested in resistant 
cells harboring elevated CRAF levels, these resistant 
cells retained sensitivity to single agent MEK inhibitor, 
suggesting that they would also be sensitive to combined 
BRAF and MEK inhibition [41]. Conversely, combined 
BRAF and MEK inhibition was not effective when tested 
in ERK-independent resistance models, presumably due 
to the activation of alternative proliferation and survival 
pathways outside of the RAF-MEK axis. Instead, 
combined inhibition of PI3K and MEK or PI3K and 
BRAF was effective in the ERK-independent models in 
which it was tested. Thus, a reasonable initial clinical 
strategy for patients who relapse on single-agent BRAF 
or MEK inhibitor would be to treat with the combination 
of a BRAF and a MEK inhibitor if their tumor harbors 
an ERK-dependent resistance mechanism or to treat 
with the combination of a PI3K inhibitor and a MEK or 
BRAF inhibitor if their resistant tumor is driven by an 
ERK-independent mechanism. Since each of these drug 
combinations is currently being evaluated in clinical 
trials, with similar combination trials being planned, it 
is feasible that this basic strategy could be implemented 
at the present time [52]. In addition, newer agents in 
development, such as ERK inhibitors, may also play a 
role in therapeutic approaches to overcome resistance in 
the future.
However, in order to apply this basic therapeutic 
strategy most effectively, it would first be necessary to 
identify whether the mechanism driving a given patient’s 
resistant tumor is ERK-dependent or ERK-independent. 
For this reason, routinely obtaining biopsies from 
recurrent tumors in patients treated with BRAF or MEK 
inhibitors will likely be important for the selection of 
the most appropriate therapy post-relapse, as has been 
done for acquired resistance to other targeted therapies 
[53]. Particularly as the frequencies of specific resistance 
mechanisms in BRAF mutant cancers become better 
understood, focused analysis of biopsies from resistant 
tumor foci for common resistance mechanisms might 
allow identification of the cause of drug resistance and 
could guide second-line therapy.
Still, while it might be feasible to screen tissue 
Table 1: Inhibitor sensitivity profiles of resistant BRAF mutant cell line models. The sensitivity of each resistant cell line model 
to BRAF inhibitor alone (BRAF), MEK inhibitor alone (MEK), the combination of a BRAF and MEK inhibitor (BRAF+MEK), and the 
combination of a PI3K inhibitor and either a RAF or MEK inhibitor (PI3K+RAF/MEK) is shown. For each condition, resistant cell line models 
are designated as sensitive (+), insensitive (-), or not tested (NT). Inhibition of proliferation without induction of apoptosis is designated as 
(+/-).
Corcoran et al, Table 1
+ - - - Jiang et al, 2010 [51] Unidentified, ?PI3K
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from resistant tumors for a small set of the most common 
individual alterations leading to resistance, the above 
studies demonstrate that resistance can arise through 
numerous specific molecular events. Therefore, especially 
as more specific mechanisms of resistance are defined, it 
may become unreasonable or even impossible to identify 
the  specific  change  driving  tumor  resistance  in  every 
patient. As a result, an alternative approach might be to 
assess resistant tumor specimens for common indicators of 
ERK-dependent or ERK-independent resistance, perhaps 
by assessing biomarkers of RAF-MEK-ERK or PI3K-
AKT signaling in a biopsy taken while the patient remains 
on treatment. For example, if P-ERK levels remain 
suppressed in a resistant tumor biopsy taken in a patient 
who remains on therapy (such as seen in the PDGFRβ-
driven model of Nazarian et al [37]), this finding would 
indicate an ERK-independent mechanism, since all ERK-
dependent mechanisms restore ERK phosphorylation 
despite the presence of inhibitor. Lack of P-ERK signal 
would suggest that this patient would best be treated with 
the combination of a PI3K inhibitor and a MEK or BRAF 
inhibitor. However, the presence of P-ERK in a resistant 
tumor biopsy does not guarantee an ERK-dependent 
mechanism, and thus it would not be possible to determine 
based on the presence of P-ERK alone whether a patient 
would benefit more from the combination of a MEK and 
a BRAF inhibitor or the combination of a PI3K inhibitor 
and a BRAF or MEK inhibitor. For example, in the RTK-
driven resistance model developed by Villanueva et al, in 
addition to the activation of an ERK-independent survival 
pathway PI3K via IGF1R, ERK phosphorylation was also 
restored in the presence of BRAF inhibitor, likely due to 
RTK-driven signals through other RAF isoforms [45]. 
Therefore, to select the optimal combination strategy, 
it might be useful to assess markers of PI3K signaling 
in addition to evaluating P-ERK levels. In fact, both 
this resistant model and clinical biopsies from resistant 
tumor with increased IGF1R activation showed elevated 
P-AKT levels. Therefore, while combined BRAF and 
MEK inhibition may be a reasonable default treatment for 
patients with clinically acquired BRAF or MEK inhibitor 
resistance, given that most resistance mechanisms 
identified to date involve ERK-dependent mechanisms, 
lack of ERK reactivation or the presence of increased 
P-AKT levels could indicate cases in which use of a PI3K 
and a MEK or BRAF inhibitor might be more effective.
Finally, it is intriguing to speculate that anticipation 
of acquired resistance to BRAF or MEK inhibitors could 
lead to strategies to prevent resistance from emerging. 
Moreover, since it is possible for multiple distinct 
resistance mechanisms to arise in the same patient, 
employing combination strategies aimed at preventing 
resistance as part of a patient’s initial therapy could have 
advantages. Recent studies have suggested that combined 
BRAF and MEK inhibition is more effective in treatment-
naïve BRAF mutant cancers than treatment with either 
inhibitor alone [39, 54]. Furthermore, one study showed 
that initial treatment with the combination of a BRAF 
and MEK inhibitors can prevent or delay emergence of 
resistance due to ERK pathway reactivation in BRAF 
mutant melanomas [54]. Similarly, initial combined 
inhibition of AKT and MEK was also shown to prevent 
resistance in BRAF mutant melanoma cell lines that 
develop resistance to MEK inhibitors through upregulation 
of PI3K-AKT signaling [55]. As a result, clinical trials 
assessing combinations of targeted inhibitors for the 
initial treatment of BRAF mutant cancers are currently 
underway [52]. Thus, identification and understanding of 
the mechanisms of resistance to BRAF or MEK inhibitors 
in BRAF mutant cancers could not only lead to strategies 
to overcome established resistance, but may yield a means 
by which to prevent resistance from emerging and to 
prolong the clinical response to therapy.
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